<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1274</article-id>
      <article-id pub-id-type="doi">10.51847/65Q1PxmAOE</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Continual Learning without Silent Change in Medication-Support Systems</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>Kim</surname>
                <given-names>Daniel</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Park</surname>
                <given-names>Jihoon</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Kang</surname>
                <given-names>Min-seo</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Jung</surname>
                <given-names>Hyun-woo</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Continual Learning and Medication Safety, College of Pharmacy, Kyung Hee University, Seoul, South Korea.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of AI Stability in Pharmacy Systems, College of Pharmacy, Chung-Ang University, Seoul, South Korea.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Non-Silent AI Updates, College of Pharmacy, Kangwon National University, Chuncheon, South Korea.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="daniel.kim@khu.ac.kr">daniel.kim@khu.ac.kr</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>30</day>
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <volume>17</volume>
      <issue>1</issue>
      <fpage>57</fpage>
      <lpage>67</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Medication-support systems may change after implementation because patient populations, clinical practices, data pipelines, coding conventions, medicine knowledge, model parameters, interfaces, and user responses evolve. Such change becomes unsafe to govern when it is not visible, version-linked, investigated, or subjected to evidence proportionate to its possible consequences. This article develops a proposed continual-learning control architecture for medication-support systems. It distinguishes continual learning from automatic production updating and defines silent change as a potentially consequential alteration in data, semantics, model behaviour, workflow position, human use, or decision effects that occurs without a contemporaneous and accountable assessment of whether requalification is required. The proposed architecture separates a locked operational plane from an isolated candidate-learning plane. Its principal components are an intended-use and change contract, multidimensional monitoring, change-event classification, an immutable version and evidence ledger, risk-proportionate requalification, staged release, rollback, suspension, and retirement. A no-silent-promotion boundary prevents a candidate version from replacing the operational version solely because retraining or automated updating has occurred. Evaluation must extend beyond discrimination to calibration, medication-task performance, workflow effects, human reliance, medication-safety signals, subgroup equity, traceability, and organizational readiness. Validation would require retrospective, external, prospective, human-factor, implementation, and post-release evidence matched to the system’s intended use and potential medication harm. The architecture does not establish clinical effectiveness, regulatory conformity, universal thresholds, or deployment readiness. Its original contribution is an integrated governance structure through which continual learning may remain technically possible while operational change remains visible, reviewable, reversible, and professionally accountable.</p>
      </abstract>
      <kwd-group>
                <kwd>Digital pharmacy</kwd>
                <kwd>Artificial intelligence</kwd>
                <kwd>Pharmacy practice</kwd>
                <kwd>Medication safety</kwd>
                <kwd>Human–AI collaboration</kwd>
                <kwd>Clinical decision support</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>